- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00003984
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
Phase II Trial With a Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients With High Risk Primary Myelodysplastic Syndromes
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have primary myelodysplastic syndrome.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES: I. Assess the therapeutic activity of monoclonal antibody HuG1-M195 on peripheral blood and bone marrow blast cell count, blood leukocyte, reticulocyte, and platelet counts, and hemoglobin levels in patients with myelodysplastic syndrome with refractory anemia with excess blasts (RAEB) (greater than 10% bone marrow myeloblasts) or RAEB in transformation. II. Assess the efficacy of this drug in terms of duration of response in these patients. III. Evaluate the toxicity of this drug in these patients.
OUTLINE: Patients receive monoclonal antibody HuG1-M195 IV over 4 hours on days 1-4. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with progressive disease after 2 courses are removed from study. Patients with stable disease receive no further treatment after 4 courses. Patients with complete or partial response receive treatment for 4 additional courses. Patients are followed at 11 and 39 days after end of course 4, monthly for 4 months, then every 3 months thereafter for 1 year from study entry.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Undersøgelsestype
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Brussels, Belgien, 1000
- Institut Jules Bordet
-
Brussels, Belgien, B-1200
- Ludwig Institute for Cancer Research-Brussels Branch
-
Edegem, Belgien, B-2650
- Universitair Ziekenhuis Antwerpen
-
Leuven, Belgien, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Herlev, Danmark, DK-2730
- Herlev Hospital - University Hospital of Copenhagen
-
-
-
-
England
-
Newcastle Upon Tyne, England, Det Forenede Kongerige, NE4 6BE
- Newcastle General Hospital
-
-
Scotland
-
Dundee, Scotland, Det Forenede Kongerige, DD1 9SY
- Ninewells Hospital and Medical School
-
Edinburgh, Scotland, Det Forenede Kongerige, EH4 9NQ
- Western General Hospital
-
Glasgow, Scotland, Det Forenede Kongerige, G61 1BD
- C.R.C. Beatson Laboratories
-
-
-
-
-
Clermont-Ferrand, Frankrig, 63011
- Centre Jean Perrin
-
Lyon, Frankrig, 69373
- Centre Leon Berard
-
Nantes-Saint Herblain, Frankrig, 44805
- CRLCC Nantes - Atlantique
-
Toulouse, Frankrig, 31052
- Institut Claudius Regaud
-
Villejuif, Frankrig, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Amsterdam, Holland, 1066 CX
- Antoni van Leeuwenhoekhuis
-
Amsterdam, Holland, 1117 MB
- Academisch Ziekenhuis der Vrije Universiteit
-
Groningen, Holland, 9713 EZ
- Academisch Ziekenhuis Groningen
-
Nijmegen, Holland, NL-6252 HB
- University Medical Center Nijmegen
-
Rotterdam, Holland, 3075 EA
- Rotterdam Cancer Institute
-
-
-
-
-
Oslo, Norge, N-0310
- Norwegian Radium Hospital
-
-
-
-
-
Basel, Schweiz, CH-4031
- University Hospital
-
Bern, Schweiz, CH-3010
- Inselspital, Bern
-
Saint Gallen, Schweiz, CH-9007
- Kantonsspital - Saint Gallen
-
-
-
-
-
Essen, Tyskland, D-45122
- Universitaetsklinik und Strahlenklinik - Essen
-
Nuremberg (Nurnberg), Tyskland, D-90419
- Klinikum Nürnberg
-
-
-
-
-
Innsbruck, Østrig, A-6020
- Innsbruck Universitaetsklinik
-
Vienna, Østrig, A-1100
- Kaiser Franz Josef Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS: Histologically confirmed primary myelodysplastic syndrome (MDS) with greater than 10% bone marrow blasts Refractory anemia with excess blasts (RAEB) OR RAEB in transformation No chronic myelomonocytic leukemia No secondary MDS after prior chemotherapy except if treatment was for acute myeloid leukemia No allogeneic bone marrow transplantation planned
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Hemoglobin no greater than 10 g/dL OR transfusion requirement of at least 3 packs of RBCs per month OR Platelet count less than 50,000/mm3 OR Absolute neutrophil count less than 1,000/mm3 No disseminated intravascular coagulation defined as fibrinogen less than 100 mg/dL AND prolonged PT, PTT, or thrombin time AND platelet count less than 25,000/mm3 without transfusion Hepatic: Bilirubin no greater than 2.0 mg/dL Alkaline phosphatase no greater than 4 times upper limit of normal (ULN) (unless due to underlying disease or Gilbert's syndrome) SGPT and SGOT no greater than 4 times ULN (unless due to underlying disease or Gilbert's syndrome) Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No uncontrolled hypertension No congestive heart failure, cardiac arrhythmia, or angina pectoris No history of myocardial infarction within the past 6 months No other significant cardiovascular disease LVEF within normal range by MUGA or echocardiogram No active ischemia Pulmonary: No pulmonary dysfunction Other: No central or peripheral neuropathy No uncontrolled or unstable diabetes No other significant organ system dysfunction HIV negative No prior malignancy except basal cell carcinoma or carcinoma in situ of the uterus No active, uncontrolled infection Not pregnant or nursing Fertile patients must use effective contraception during and for 3 months after study
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 2 months since prior biologic therapy (e.g., hematopoietic growth factors or biological response modifiers) Chemotherapy: See Disease Characteristics At least 2 months since prior chemotherapy Endocrine therapy: At least 2 months since prior endocrine therapy Radiotherapy: At least 2 months since prior radiotherapy Concurrent radiotherapy allowed Surgery: At least 2 months since prior surgery Other: No other concurrent investigational drugs
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Heinz Zwierzina, MD, Medical University Innsbruck
Datoer for undersøgelser
Studer store datoer
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EORTC-13981
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Myelodysplastiske syndromer
-
University of Colorado, DenverRekrutteringKlinefelters syndrom | Trisomi X | XYY syndrom | XXXY og XXXXY syndrom | Xxyy syndrom | Xyyy syndrom | Xxxx syndrom | Xxxxx syndrom | Xxxyy syndrom | Xxyyy syndrom | Xyyyy syndrom | Mand med sexkromosommosaicismeForenede Stater
-
Riphah International UniversityAfsluttet
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Riphah International UniversityRekrutteringNedre kors syndromPakistan
-
Foundation University IslamabadRekruttering
-
University of CalgaryUkendtNefrotisk syndrom hos børn | Nefrotisk syndrom, minimal ændring | Nefrotisk syndrom, idiopatiskCanada
Kliniske forsøg med lintuzumab
-
Actinium PharmaceuticalsAfsluttetRefraktær MyelomForenede Stater
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Ukendt
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AfsluttetMyelodysplastiske syndromer | LeukæmiForenede Stater
-
Seagen Inc.AfsluttetAkut myeloid leukæmi | Myeloproliferative lidelser | Kronisk myelomonocytisk leukæmi | Myelodysplastisk syndromForenede Stater
-
Medical College of WisconsinAktiv, ikke rekrutterendeAkut myeloid leukæmiForenede Stater
-
Joseph JurcicTrukket tilbageAkut myeloid leukæmi
-
Seagen Inc.AfsluttetMyelodysplastisk syndrom (MDS)Forenede Stater
-
Alison WalkerSeagen Inc.AfsluttetMyelodysplastiske syndromer | LeukæmiForenede Stater
-
Actinium PharmaceuticalsTrukket tilbageAkut myeloid leukæmi | Tilbagefaldende voksen AML
-
M.D. Anderson Cancer CenterAfsluttetAkut myeloid leukæmi | Myeloproliferative lidelser | Kronisk myelomonocytisk leukæmi | Anæmi, ildfast, med overskud af eksplosionerForenede Stater